Navigation Links
Incorrectly cleaved protein leads to schizophrenia
Date:7/14/2008

Leuven, Belgium Schizophrenia is a disease that strikes an average of 4000 Belgians every year. The causes of this psychiatric disorder are not yet clear. But now, VIB researchers connected to the Katholieke Universiteit Leuven have discovered that a disturbed cleavage of the Nrg-1 protein lies at the basis of the development of the disease. Greater understanding of this molecular process is a first step toward improved diagnosis and more effective treatment of schizophrenia and other related disorders.

What is schizophrenia?

Schizophrenia is a mental disorder that appears in about 1 out of every 250 Belgians, manifesting most often between the ages of 15 and 30. This disease of the brain seriously disturbs the person's thinking, emotional life, and behavior. The disease is characterized by episodes of psychotic symptoms: abnormal ideas and changes in perception, behavior and thinking occur, through which it is difficult to understand how the person feels. Typical symptoms of the disorder are: delusions, hallucinations, chaotic behavior, etc.

The origin of the disease

Up to now, no clear cause of schizophrenia has been found, although hereditary factors certainly play a role in the development of the disease. In addition, living and working conditions determine the disorder's progress. Research into schizophrenia has also shown that there is a disturbance of the activity of the frontal and temporal areas in the brain, which is connected with a disturbed equilibrium among the substances (proteins) that are needed for neuronal functioning. Schizophrenia is treated using anti-psychotic and neuroleptic medicines.

Research leads to new insights into the molecular causes

The molecular story hidden behind schizophrenia is still not at all clear. However, previous scientific studies have indeed shown that a disturbed functioning of the Nrg-1 protein is linked to the development of the disease. Now, the recent research results obtained by Tim Dejaegere and his colleagues connected to VIB and K.U.Leuven reveal how the functioning of Nrg-1 becomes disturbed.

The Nrg-1 protein − an essential factor in the development and proper functioning of our nervous system and, consequently, in the functioning of our brain − can carry out its function properly only after it has been cleaved in the right way. This cleavage is the responsibility of a molecular 'scissors' called Aph1B/C-gamma-secretase. When this scissors is absent, Nrg-1 is not cleaved, which leads to behavioral disturbances in laboratory animals that bear a striking similarity to some of the symptoms of schizophrenia. This syndrome can be corrected by administering anti-psychotic medicines. Additional studies have also shown that a genetic alteration near the site of Nrg-1 cleavage, which was detected in schizophrenia patients and which increases the risk of this disease, results in incorrect cleavage of Nrg-1 by the gamma-secretase.

The researchers are suggesting that a disturbed cleavage of Nrg-1 plays a crucial role in the development of schizophrenia and other related psychiatric disorders. This discovery is a new step forward in the quest for improved diagnosis and targeted treatment of the disease.


'/>"/>

Contact: Joke Comijn
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
4. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
7. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
8. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
11. Immune system protein starves staph bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading ... grant applications subject to the existing policy. AMIA recommended that NIH earmark funding ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type ... tremendous growth is accounted to two main factors. The first is the amazing ... of vendors supplying FireflySci products all around the world. , 2016 was a tremendous ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):